| Literature DB >> 35478735 |
Erin D Reilly1,2, Elizabeth S Chamberlin1, Brooke A Duarte3, J Irene Harris1,4, Steven D Shirk1,2, Megan M Kelly1,2.
Abstract
As the COVID-19 pandemic sweeps the globe, many veterans with substance use issues have faced the closure of treatment facilities, mandates to shelter in place, and social distancing measures. To better understand their pandemic experiences, substance use changes, and functioning, a survey was nationally administered to a sample of United States veterans reporting substance use issues during the pandemic. The purpose of this cross-sectional online survey for veterans (N = 409) was to report on COVID-19 experiences, safety behaviors, and infection experiences while also investigating the relationship among addictive behaviors, mental and physical health, and COVID-19 impact. Measures also assessed specific substance use concerns, pandemic-related loneliness, and functioning. Though few veterans reported personally receiving a confirmed COVID-19 medical diagnosis (10.5%), the impact of pandemic stressors was evident, with a majority reporting anxiety related to contracting COVID-19 (61.4%) or fear of a family member or close friend contracting COVID-19 (58.7%). Participants reported increased use of alcohol (45.3%), sedatives (36.6%), inhalants (35.7%), tobacco (35.0%), and cannabis (34.9%), attributed specifically to the pandemic. Regression analyses revealed that even when controlling for the contribution of problematic substance use issues, negative pandemic impacts and self-reported COVID-19 related loneliness were related to more impaired physical and mental health functioning during the pandemic. Findings from this sample of veterans with addiction issues add to the growing literature suggesting unique and adverse effects of COVID-19 stressors on functioning while also revealing specific pandemic impacts for this group.Entities:
Keywords: addiction; functioning; pandemic (COVID19); substance use disorders; veterans
Year: 2022 PMID: 35478735 PMCID: PMC9035845 DOI: 10.3389/fpsyg.2022.812247
Source DB: PubMed Journal: Front Psychol ISSN: 1664-1078
Sample demographics (N = 409).
| Variable | Frequency (%) | Variable | Frequency (%) |
|---|---|---|---|
|
|
| ||
| Male | 313 (76.5%) | Less than $19,999 | 31 (7.60%) |
| Female | 94 (23%) | $20,000–39,999 | 70 (17.11%) |
| Transgender Male | 1 (0.2%) | $40,000–59,999 | 66 (16.14%) |
| Preferred not to answer | 1 (0.2%) | $60,000–79,999 | 53 (12.96%) |
| Age | $80,000–99,999 | 48 (11.74%) | |
| $100,000–149,999 | 87 (21.30%) | ||
| White | 370 (90.50%) | $150,000 + | 54 (13.20%) |
| Black/African American | 22 (5.40%) |
| |
| Other | 7 (1.70%) | Married | 273 (66.70%) |
| Asian | 5 (1.20%) | Divorced | 47 (11.50%) |
| Native Hawaiian/Pacific Islander | 5 (1.20%) | Single, never married | 39 (9.50%) |
| American Indian/Alaska Native | 5 (1.20%) | In a relationship, not married | 24 (5.90%) |
|
| Widowed | 15 (3.70%) | |
| Not Hispanic/Latino | 376 (91.90%) | Separated | 11 (2.70%) |
| Hispanic/Latino | 33 (8.10%) | ||
|
| Army | 202 (49.40%) | |
| Heterosexual (straight) | 374 (91.40%) | Air Force | 81 (19.80%) |
| Bisexual | 19 (4.6%) | Navy | 65 (15.90%) |
| Homosexual (gay) | 13 (3.2%) | Marines | 44 (10.80%) |
| Prefer not to say | 3 (0.70%) | National Guard | 29 (7.10%) |
| National Reserve | 11 (2.70%) | ||
| September 2001 or later | 156 (38.1%) | Coast Guard | 7 (1.70%) |
| August 1990–August 2001 | 96 (23.5%) | Army Reserves | 1 (0.20%) |
| May 1975–July 1990 | 99 (24.2%) | Connected to VHA Care | 268 (65.5%) |
| Vietnam Era (1964–1975) | 150 (36.7%) | ||
| February 1955–July 1964 | 24 (5.9%) | ||
| Korean War (1950–1955) | 3 (0.7%) |
Participants could choose multiple categories.
Veteran sample substance use, psychiatric, and physical health diagnoses.
| Substance use diagnoses | Frequency (%) |
|---|---|
| Alcohol Use Disorder | 113 (27.6%) |
| Substance Use Disorder | 84 (20.5%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anxiety Disorder | 149 (36.4%) |
| Post-Traumatic Stress Disorder | 112 (27.4%) |
| Major Depressive Disorder | 83 (20.3%) |
| Panic Disorder | 48 (11.7%) |
| Bipolar Disorder | 31 (7.6%) |
| Schizophrenia | 9 (2.2%) |
| Psychogenic non-epileptic seizures (PNES) | 7 (1.7%) |
|
|
|
| Chronic Pain | 129 (31.5%) |
| Diabetes | 73 (17.8%) |
| Insomnia | 70 (17.1%) |
| Heart Disease | 48 (11.7%) |
| Apnea | 47 (11.5%) |
| Seizures | 16 (3.9%) |
Participants could choose multiple categories.
Alcohol and non-prescription substance use, urges, and changes in use due to COVID-19.
| Alcohol | Tobacco | Cannabis | Sedatives | Opioids | Stimulants | Cocaine | Inhalants | Hallucinogen | |
|---|---|---|---|---|---|---|---|---|---|
| Lifetime/Any Use | 397 (97.1%) | 334 (81.7%) | 255 (62.3%) | 161 (39.4%) | 109 (26.7%) | 105 (25.7%) | 95 (23.2%) | 42 (10.3%) | 74 (18.1%) |
|
| |||||||||
| Not at all | 39 (9.8%) | 113 (33.8%) | 84 (32.9%) | 23 (14.3%) | 34 (21.2%) | 39 (37.1%) | 49 (51.6%) | 6 (14.3%) | 39 (52.7%) |
| Once or twice | 16 (4.0%) | 20 (6.0%) | 26 (10.2%) | 19 (11.8%) | 17 (15.6%) | 18 (17.1%) | 10 (10.5%) | 9 (21.4%) | 7 (9.5%) |
| Monthly | 29 (7.3%) | 16 (4.8%) | 25 (9.8%) | 16 (9.9%) | 13 (11.9%) | 11 (10.5%) | 9 (9.5%) | 5 (11.9%) | 6 (8.1%) |
| Weekly | 131 (33.0%) | 35(10.5%) | 60 (23.5%) | 55 (34.2%) | 16 (14.7%) | 21 (20.0%) | 15 (15.8%) | 16 (38.1%) | 17 (23.0%) |
| Daily or mostly daily | 182 (45.8%) | 150 (44.9%) | 60 (23.5%) | 48 (29.8%) | 29 (26.6%) | 16 (15.2%) | 12 (12.6%) | 6 (14.3%) | 5 (6.8%) |
| Lower urge/craving | 54 (13.6%) | 43 (12.9%) | 32 (12.5%) | 34 (21.2%) | 16 (14.7%) | 18 (17.1%) | 10 (10.5%) | 13 (31.0%) | 6 (8.1%) |
| No change in urge/craving | 154 (38.8%) | 167 (50.0%) | 125 (49.0%) | 68 (42.2%) | 55 (50.5%) | 52 (49.5%) | 59 (62.1%) | 16 (38.1%) | 49 (66.2%) |
| Higher urge/craving | 189 (47.6%) | 124 (37.1%) | 98 (38.4%) | 59 (36.6%) | 38 (34.9%) | 35 (33.3%) | 26 (27.4%) | 13 (31.0%) | 19 (25.7%) |
| Decreased use | 68 (17.1%) | 49 (14.7%) | 32 (12.5%) | 30 (18.6%) | 19 (17.4%) | 21 (20.0%) | 11 (11.6%) | 12 (28.6%) | 5 (6.8%) |
| No change in use | 149 (36.4%) | 168 (50.3%) | 134 (52.5%) | 72 (44.7%) | 60 (55.0%) | 51 (48.6%) | 61 (64.2%) | 15 (35.7%) | 50 (67.6%) |
| Increased use | 180 (45.3%) | 117 (35.0%) | 89 (34.9%) | 59 (36.6%) | 30 (27.5%) | 33 (31.4%) | 23 (24.2%) | 15 (35.7%) | 19 (25.7%) |
Percentage of changes in urges and use based only on participants reporting lifetime/any use for the specific substance.
Veteran experiences with COVID-19 health, stressors, and safety behaviors.
| COVID-19 infection experiences | Frequency (%) |
|---|---|
| Received COVID-19 medical diagnosis | 43 (10.5%) |
| Believe they had COVID-19, not officially diagnosed | 52 (12.7%) |
| Average number of days experiencing symptoms | 11.3 ( |
| Hospitalized due to COVID-19 | 2 (0.5%) |
| Received COVID-19 vaccine | 14 (3.4%) |
| A family member/close friend was diagnosed | 136 (33.3%) |
| A family member/close friend died | 53 (13%) |
| COVID-19 Stressors | Frequency (%) |
| Getting COVID-19 | 251 (61.4%) |
| Someone close to participant getting COVID-19 | 240 (58.7%) |
| Feeling isolated and alone | 148 (36.2%) |
| Worries about finances/income | 134 (32.8%) |
| Not getting necessary medical care | 99 (24.2%) |
| Meeting basic needs (e.g., food, housing) | 92 (22.5%) |
| Having difficulty meeting conditions of probation/parole | 16 (3.9%) |
| No worries or stressors related to COVID-19 | 6 (1.4%) |
| COVID-19 Safety Behaviors | Frequency (%) |
| Wore a facemask | 363 (88.8%) |
| Avoided public spaces/crowds | 283 (69.2%) |
| Avoided in-person contact with friends/family | 205 (50.1%) |
| Cancelled/postponed travel | 197 (48.2%) |
| Had a telehealth visit | 136 (33.3%) |
| Had an in-person healthcare visit | 124 (30.3%) |
| Stockpiled food and/or water | 118 (28.9%) |
| Teleworked | 101 (24.7%) |
| Prayed/meditated/engaged in spiritual practice | 96 (23.5%) |
| Cancelled a healthcare appointment | 73 (17.8%) |
| Cancelled/postponed work or school activities | 51 (12.5%) |
| No safety behaviors used | 7 (1.7%) |
Vaccination item added 14/12/2021, available to 75.8% of participants.
Correlations among continuous predictor variables.
| Measure | 1 | 2 | 3 | 4 | 5 | 6 |
|---|---|---|---|---|---|---|
| 1. Age | - | |||||
| 2. CAGE-AID | −0.33 | - | ||||
| 3. PMC-5 | −0.31 | 0.31 | ||||
| 4. ULS-8 | −0.28 | 0.28 | −0.49 | |||
| 5. PCS-12 | 0.10 | −0.14 | −0.24 | −0.24 | ||
| 6. MCS-12 | 0.28 | −0.24 | −0.33 | −0.45 | −0.19 | -- |
|
| 54.84 | 2.37 | 2.46 | 18.30 | 43.31 | 42.48 |
|
| 56.00 | 2.00 | 2.40 | 18.00 | 43.95 | 43.06 |
|
| 16.44 | 1.12 | 0.57 | 5.44 | 6.79 | 6.78 |
| Range | 19–88 | 1–4 | 1–4 | 8–32 | 24.56–59.81 | 19.91–63.72 |
CAGE-AID, CAGE adapted to include drugs scale; ULS-8 Loneliness, UCLA Loneliness Scale-8; PMC-5, Pandemic Impact: Pain Management Collaboratory (PMC) 5-Item COVID Negative Impact Measure; MCS-12, Short-Form Health Survey’s (SF-12) Mental health component scale; and PCS-12, Short-Form Health Survey’s (SF-12) Physical health component scale.
p < 0.05,
p < 0.01, and
p < 0.001.
Summary of hierarchical regression analysis predicting mental and physical health functioning (n = 409).
| Step and Variable | Mental Health Functioning | Physical Health Functioning | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
| Adjusted |
|
|
|
| Adjusted | |
| Step 1 | 0.09 | 0.04 | ||||||||
| Age | 0.11 | 0.02 | 0.27 | 0.07 | 0.05 | 0.02 | 0.09 | 0.02 | ||
| Gender | 1.30 | 0.81 | 0.08 | 0.01 | 0.16 | 0.84 | 0.01 | 0.00 | ||
| Income | 0.14 | 0.10 | 0.07 | 0.00 | 0.36 | 0.10 | 0.18 | 0.03 | ||
| Step 2 | 0.12 | 0.04 | ||||||||
| Age | 0.09 | 0.02 | 0.21 | 0.02 | 0.04 | 0.02 | 0.09 | 0.01 | ||
| Gender | 1.50 | 0.80 | 0.09 | 0.01 | 0.28 | 0.84 | 0.02 | 0.00 | ||
| Income | 0.11 | 0.10 | 0.05 | 0.00 | 0.34 | 0.10 | 0.17 | 0.03 | ||
| CAGE-AID | −1.00 | 0.30 | −0.17 | 0.02 | −0.62 | 0.31 | −0.10 | 0.01 | ||
| Step 3 | 0.23 | 0.08 | ||||||||
| Age | 0.05 | 0.02 | 0.12 | 0.01 | 0.02 | 0.02 | 0.04 | 0.00 | ||
| Gender | 0.38 | 0.76 | 0.02 | 0.00 | −0.37 | 0.84 | −0.02 | 0.00 | ||
| Income | −0.07 | 0.09 | −0.04 | 0.00 | 0.23 | 0.10 | 0.12 | 0.01 | ||
| CAGE-AID | −0.43 | 0.29 | −0.07 | 0.00 | −0.28 | 0.32 | −0.05 | 0.00 | ||
| ULS-8 | −0.42 | 0.07 | −0.34 | 0.08 | −0.18 | 0.07 | −0.14 | 0.01 | ||
| PMC-5 | −1.37 | 0.63 | −0.12 | 0.01 | −1.35 | 0.69 | −0.11 | 0.01 | ||
| PMC-5 × ULS-8 | −0.97 | 0.09 | −0.05 | 0.30 | 0.07 | 0.10 | 0.03 | 0.51 | ||
CAGE-AID, CAGE adapted to include drugs scale; ULS-8: Loneliness, UCLA Loneliness Scale-8; and PMC-5, Pandemic Impact: Pain Management Collaboratory (PMC) 5-Item COVID Negative Impact Measure.
p < 0.05,
p < 0.01, and
p < 0.001.